Caffeic Acid

Caffeic Acid

SCHEMBL29353048

O=C(O)/C=C/c1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
HSD17B10 Q99714 3/20 1.00
CA12 O43570 3/20 1.00
CA1 P00915 3/20 1.00
CA2 P00918 3/20 1.00
CA3 P07451 3/20 1.00
CA4 P22748 3/20 1.00
CA6 P23280 3/20 1.00
CA5A P35218 3/20 1.00
CA7 P43166 3/20 1.00
CA9 Q16790 3/20 1.00
CA14 Q9ULX7 3/20 1.00
CA5B Q9Y2D0 3/20 1.00
MAPT P10636 2/20 1.00
TTR P02766 2/20 1.00
APP P05067 2/20 1.00
AKR1B10 O60218 2/20 1.00
AKR1B1 P15121 2/20 1.00
DPP4 P27487 2/20 1.00
MMP1 P03956 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Caffeic Acid SCHEMBL23359 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL30501140 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL29447135 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL30050844 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL3682144 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL7064846 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL23358 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL1262229 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL21114743 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL9477189 0.98 KDM4E (0.96) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111787892-B Chitosan material resistant to tissue adhesion by dissolution 金珂生物医疗公司 2025-02-18 CN claimed
CN-116236491-A Application of rhamnose in preparing medicine for treating or preventing neurodegenerative diseases, pharmaceutical composition and application thereof 海南先声药业有限公司 2023-06-09 CN claimed
CN-113968795-A Compound, composition and application of compound and composition in preparation of medicine with effect of treating myocarditis 潍坊市人民医院(潍坊市传染病医院) 2022-01-25 CN claimed
EP-4630006-A1 FLOWABLE CHITOSAN BIOADHESIVE HEMOSTATIC COMPOSITIONS THAT RESIST DISSOLUTION Tricol Biomedical, Inc. (US) 2025-10-15 EP disclosed
WO-2025135133-A1 AGENT FOR USE IN MAINTAINING STRUCTURE OF HYALURONIC ACID 一丸ファルコス株式会社 2025-06-26 WO disclosed
CN-111787892-B Chitosan material resistant to tissue adhesion by dissolution 金珂生物医疗公司 2025-02-18 CN disclosed
CN-119371432-A Alpha-mangostin derivative and preparation method and application thereof 上海如凌生物医药有限公司 2025-01-28 CN disclosed
US-20250002490-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) 2025-01-02 US disclosed
CN-119039366-A Keap 1-targeted glycoside compound and preparation method and application thereof 中医药广东省实验室 2024-11-29 CN disclosed
CN-119032076-A Novel compounds and uses thereof 株式会社安提昂 2024-11-26 CN disclosed
WO-2024123809-A1 FLOWABLE CHITOSAN BIOADHESIVE HEMOSTATIC COMPOSITIONS THAT RESIST DISSOLUTION TRICOL BIOMEDICAL, INC. (US) 2024-06-13 WO disclosed
WO-2022261201-A1 DISSOLUTION RESISTANT TISSUE ADHERENT DRESSING APPLICATION AND ITS DELIVERY TRICOL BIOMEDICAL, INC. (US) 2022-12-15 WO disclosed
EP-4066302-A1 STABLE AQUEOUS COMPOSITIONS COMPRISING QUINONES, AND USE THEREOF IN REDOX FLOW BATTERIES Technische Universität Graz (AT) 2022-10-05 EP disclosed
CN-105283547-B Recombinant host cells for biosynthetic production 罗地亚经营管理公司 2022-10-04 CN disclosed
WO-2022200352-A1 USE OF ACTIVE SUBSTANCES OF PLANT ORIGIN FOR THE TREATMENT OF COVID-19 Universität Duisburg-Essen (DE) 2022-09-29 WO disclosed
CN-114957053-A Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof 中国医学科学院医药生物技术研究所 2022-08-30 CN disclosed
CN-114599772-A Metal complexes and their use 罗地亚经营管理公司 2022-06-07 CN disclosed
CN-114539092-A Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of itching-relieving products 深圳海创生物科技有限公司 2022-05-27 CN disclosed
US-20220087952-A1 ANTI-APICOMPLEXAN COMPOSITIONS THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (IL) 2022-03-24 US disclosed
CN-113968795-A Compound, composition and application of compound and composition in preparation of medicine with effect of treating myocarditis 潍坊市人民医院(潍坊市传染病医院) 2022-01-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002490-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.